{"id":"https://openalex.org/W3033370892","doi":"https://doi.org/10.1200/jco.2020.38.18_suppl.lba5","title":"Osimertinib as adjuvant therapy in patients (pts) with stage IB\u2013IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.","display_name":"Osimertinib as adjuvant therapy in patients (pts) with stage IB\u2013IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.","publication_year":2020,"publication_date":"2020-06-01","ids":{"openalex":"https://openalex.org/W3033370892","doi":"https://doi.org/10.1200/jco.2020.38.18_suppl.lba5","mag":"3033370892"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.18_suppl.lba5","doi":"https://doi.org/10.1200/jco.2020.38.18_suppl.lba5","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.18_suppl.lba5","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008593691","display_name":"Roy S. Herbst","orcid":"https://orcid.org/0000-0003-2535-5847","observed_orcids":["https://orcid.org/0000-0003-2535-5847"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roy S. Herbst","raw_affiliation_strings":["Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT;","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045498137","display_name":"Masahiro Tsuboi","orcid":"https://orcid.org/0000-0003-3031-5807","observed_orcids":["https://orcid.org/0000-0003-3031-5807"]},"institutions":[{"id":"https://openalex.org/I4210145079","display_name":"National Cancer Center Hospital East","ror":"https://ror.org/03rm3gk43","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210145079"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masahiro Tsuboi","raw_affiliation_strings":["Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Chiba, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Chiba, Japan;","institution_ids":["https://openalex.org/I4210145079"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089757931","display_name":"Thomas John","orcid":"https://orcid.org/0000-0003-3399-5342","observed_orcids":["https://orcid.org/0000-0003-3399-5342"]},"institutions":[{"id":"https://openalex.org/I4210163497","display_name":"Austin Health","ror":"https://ror.org/05dbj6g52","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210163497"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Thomas John","raw_affiliation_strings":["Department of Medical Oncology, Austin Health, Heidelberg, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Austin Health, Heidelberg, Australia;","institution_ids":["https://openalex.org/I4210163497"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114929422","display_name":"Christian Groh\u00e9","orcid":"https://orcid.org/0000-0003-2724-7647","observed_orcids":["https://orcid.org/0000-0003-2724-7647"]},"institutions":[{"id":"https://openalex.org/I4210150902","display_name":"Evangelische Lungenklinik Berlin","ror":"https://ror.org/05q4r1796","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210145344","https://openalex.org/I4210150902"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Christian Groh\u00e9","raw_affiliation_strings":["Klinik f\u00fcr Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Klinik f\u00fcr Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany;","institution_ids":["https://openalex.org/I4210150902"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059355812","display_name":"Margarita Majem","orcid":"https://orcid.org/0000-0002-9919-7485","observed_orcids":["https://orcid.org/0000-0002-9919-7485"]},"institutions":[{"id":"https://openalex.org/I2801795740","display_name":"Hospital de Sant Pau","ror":"https://ror.org/059n1d175","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2801795740"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Margarita Majem","raw_affiliation_strings":["Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;","institution_ids":["https://openalex.org/I2801795740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036134937","display_name":"Jonathan Wade Goldman","orcid":"https://orcid.org/0000-0002-4925-8243","observed_orcids":["https://orcid.org/0000-0002-4925-8243"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Wade Goldman","raw_affiliation_strings":["David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA;","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046400988","display_name":"Sang\u2010We Kim","orcid":"https://orcid.org/0000-0003-1065-8095","observed_orcids":["https://orcid.org/0000-0003-1065-8095"]},"institutions":[{"id":"https://openalex.org/I2801680663","display_name":"Asan Medical Center","ror":"https://ror.org/03s5q0090","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2801680663","https://openalex.org/I4210167194"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Sang-We Kim","raw_affiliation_strings":["Department of Oncology, Asan Medical Center, Seoul, Korea, Republic of (South);"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Asan Medical Center, Seoul, Korea, Republic of (South);","institution_ids":["https://openalex.org/I2801680663"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060970786","display_name":"Dominika Marmol","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dominika Marmol","raw_affiliation_strings":["Late Oncology Statistics, AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Late Oncology Statistics, AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020813615","display_name":"Yuri Rukazenkov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Yuri Rukazenkov","raw_affiliation_strings":["Oncology Research & Development, AstraZeneca, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Research & Development, AstraZeneca, Cambridge, United Kingdom;","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100632072","display_name":"Yi-Long Lung Cancer Wu","orcid":"https://orcid.org/0000-0002-3611-0258","observed_orcids":["https://orcid.org/0000-0002-3611-0258"]},"institutions":[{"id":"https://openalex.org/I4210145693","display_name":"Guangdong Academy of Medical Sciences","ror":"https://ror.org/0432p8t34","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210145693"]},{"id":"https://openalex.org/I4210153930","display_name":"Guangdong Provincial People's Hospital","ror":"https://ror.org/045kpgw45","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210153930"]},{"id":"https://openalex.org/I90610280","display_name":"South China University of Technology","ror":"https://ror.org/0530pts50","country_code":"CN","type":"education","lineage":["https://openalex.org/I90610280"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yi-Long Wu","raw_affiliation_strings":["Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China;","institution_ids":["https://openalex.org/I4210145693","https://openalex.org/I4210153930","https://openalex.org/I90610280"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":95,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"18_suppl","first_page":"LBA5","last_page":"LBA5"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":0.9679999947547913},{"id":"https://openalex.org/keywords/early-stage-non-small-cell-lung-cancer","display_name":"early-stage non-small cell lung cancer","score":0.8949999809265137},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.9409999847412109},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.7919999957084656},{"id":"https://openalex.org/keywords/disease-free-survival","display_name":"disease-free survival","score":0.828000009059906},{"id":"https://openalex.org/keywords/ex19del","display_name":"ex19del","score":0.6930000185966492},{"id":"https://openalex.org/keywords/l858r","display_name":"L858R","score":0.9520000219345093},{"id":"https://openalex.org/keywords/complete-tumor-resection","display_name":"total tumor resection","score":0.6439999938011169},{"id":"https://openalex.org/keywords/adaura-trial","display_name":"ADAURA trial","score":0.6990000009536743},{"id":"https://openalex.org/keywords/interim-analysis","display_name":"interim analysis","score":0.7450000047683716},{"id":"https://openalex.org/keywords/asian-patients","display_name":"Asian patients","score":0.4650000035762787},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.39899998903274536},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.4749999940395355},{"id":"https://openalex.org/keywords/recurrence-prevention","display_name":"recurrence prevention","score":0.36000001430511475}],"concepts":[{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.9341316223144531},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9326332807540894},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.6879977583885193},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6725215911865234},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6593104600906372},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.6358144283294678},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5906293392181396},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5430142879486084},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.5316793322563171},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.49760130047798157},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.4635339081287384},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.35783660411834717},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3446286916732788},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.286928653717041},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.1563534438610077},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C81729549","wikidata":"https://www.wikidata.org/wiki/Q4649475","display_name":"A549 cell","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.18_suppl.lba5","doi":"https://doi.org/10.1200/jco.2020.38.18_suppl.lba5","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.18_suppl.lba5","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4297984405","https://openalex.org/W4379662232","https://openalex.org/W4327935238","https://openalex.org/W4226080635","https://openalex.org/W4319455781","https://openalex.org/W4310753261","https://openalex.org/W4389850548","https://openalex.org/W2765911811","https://openalex.org/W4385576243","https://openalex.org/W4318693852"],"abstract_inverted_index":{"LBA5":[0],"Background:":[1],"Osimertinib":[2],"is":[3,33,39,67,320],"a":[4,68,326,331],"3rd-generation,":[5],"CNS-active,":[6],"EGFR-TKI":[7,13],"with":[8,24,27,45,86,143,261,265,285,289,296,310,342],"superior":[9],"efficacy":[10,76],"to":[11,112,156,165,170,214,329],"comparator":[12],"(gefitinib/erlotinib)":[14],"in":[15,43,84,191,325,338,340],"treatment-na\u00efve":[16],"EGFRm":[17,89,136,345],"advanced":[18],"NSCLC.":[19],"Approx.":[20],"30%":[21],"of":[22,41,79,140,315],"pts":[23,44,85,211,341],"NSCLC":[25,49,90,142,346],"present":[26],"early":[28,110],"stage":[29,47,52,87,132,176,192,227,230,240,343],"(I\u2013IIIA)":[30],"disease;":[31],"surgery":[32],"the":[34,75,106,268,311,321],"primary":[35,130,141],"treatment.":[36],"Adjuvant":[37,318,356],"chemotherapy":[38,149],"standard":[40],"care":[42],"resected":[46],"II\u2013III":[48],"and":[50,60,77,95,173,181,200,334,351],"select":[51],"IB":[53,228],"pts;":[54],"however,":[55],"recurrence":[56],"rates":[57],"are":[58,63],"high":[59],"other":[61],"therapies":[62],"needed.":[64],"ADAURA":[65],"(NCT02511106)":[66],"Ph":[69],"III,":[70],"double-blind,":[71],"randomized":[72,154,213],"study":[73],"assessing":[74],"safety":[78,306,313],"osimertinib":[80,157,216,262,286,319,357],"vs":[81,263,287],"placebo":[82],"(PBO)":[83],"IB\u2013IIIA":[88],"after":[91,347],"complete":[92,138,348],"tumor":[93,349],"resection":[94,139,350],"adjuvant":[96,352],"chemotherapy,":[97,353],"when":[98,354],"indicated.":[99,355],"Following":[100],"Independent":[101],"Data":[102,202],"Monitoring":[103],"Committee":[104],"recommendation,":[105],"trial":[107,328,368],"was":[108,150,247,259,273,283,292,308],"unblinded":[109],"due":[111],"efficacy;":[113],"we":[114],"report":[115],"an":[116,359],"unplanned":[117],"interim":[118],"analysis.":[119],"Methods:":[120],"Eligible":[121],"pts:":[122],"\u226518":[123],"years":[124,172],"(Japan/Taiwan:":[125],"\u226520),":[126],"WHO":[127],"PS":[128],"0/1,":[129],"non-squamous":[131],"IB/II/IIIA":[133,344],"NSCLC,":[134],"confirmed":[135],"(ex19del/L858R),":[137,180],"full":[144],"recovery":[145],"from":[146],"surgery;":[147],"postoperative":[148],"allowed.":[151],"Pts":[152],"were":[153,212,222],"1:1":[155],"80":[158],"mg":[159],"once":[160],"daily":[161],"orally":[162],"or":[163],"PBO":[164,218,301],"receive":[166],"treatment":[167,362],"for":[168,364],"up":[169],"3":[171],"stratified":[174],"by":[175,189],"(IB/II/IIIA),":[177],"mutation":[178],"type":[179],"race":[182],"(Asian/non-Asian).":[183],"Primary":[184],"endpoint:":[185],"disease-free":[186],"survival":[187,198],"(DFS)":[188],"investigator":[190],"II\u2013IIIA":[193,241],"pts.":[194,366],"Secondary":[195],"endpoints:":[196],"overall":[197,269],"(OS)":[199],"safety.":[201],"cutoff":[203],"(DCO):":[204],"17":[205],"Jan":[206],"2020.":[207],"Results:":[208],"Globally,":[209],"682":[210],"treatment:":[215],"n=339,":[217],"n=343.":[219],"Baseline":[220],"characteristics":[221],"balanced":[223],"across":[224],"arms":[225],"(osimertinib/PBO):":[226],"31/31%,":[229],"II/IIIA":[231],"69/69%,":[232],"female":[233],"68/72%,":[234],"ex19del":[235],"55/56%,":[236],"L858R":[237],"45/44%.":[238],"In":[239,267],"pts,":[242],"DFS":[243,257,271,281,339],"hazard":[244],"ratio":[245],"(HR)":[246],"0.17":[248],"(95%":[249],"CI":[250],"0.12,":[251],"0.23);":[252],"p<0.0001":[253,277],"(156/470":[254],"events);":[255,279],"2-year":[256,280],"rate":[258,282],"90%":[260],"44%":[264],"PBO.":[266,290],"population,":[270],"HR":[272],"0.21":[274],"(0.16,":[275],"0.28);":[276],"(196/682":[278],"89%":[284],"53%":[288],"OS":[291],"immature":[293],"(4%":[294],"maturity)":[295],"29/682":[297],"deaths":[298],"(osimertinib":[299],"n=9,":[300],"n=20)":[302],"at":[303],"DCO.":[304],"The":[305],"profile":[307,314],"consistent":[309],"known":[312],"osimertinib.":[316],"Conclusions:":[317],"1st":[322],"targeted":[323],"agent":[324],"global":[327],"show":[330],"statistically":[332],"significant":[333],"clinically":[335],"meaningful":[336],"improvement":[337],"provides":[358],"effective":[360],"new":[361],"strategy":[363],"these":[365],"Clinical":[367],"information:":[369],"NCT02511106":[370],".":[371]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":12},{"year":2021,"cited_by_count":42},{"year":2020,"cited_by_count":23}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2020-06-12T00:00:00"}